Benzinga··Vandana SinghImmunityBio Surges 10% on NK Cell Therapy Manufacturing Milestone
ImmunityBio shares surge 10.6% after completing NK cell manufacturing programs producing five billion cells safely, plus FDA acknowledges ANKTIVA resubmission for bladder cancer.
IBRXBBPclinical trialbladder cancer